Pediatric Rhabdomyolysis 

  • Author: Eyal Muscal, MD; Chief Editor: Lawrence K Jung, MD   more...
 
Updated: Apr 27, 2010
 

Background

Rhabdomyolysis is a syndrome caused by injury to skeletal muscle and involves leakage of large quantities of intracellular contents into plasma.[1] It translates to "dissolution of skeletal muscle" and is a final pathway of diverse processes and insults.[2] In adults, rhabdomyolysis is characterized by the triad of muscle weakness, myalgias, and dark urine;[3] however, all 3 symptoms are rarely seen together in many children with this condition.[4, 5] Myalgias and generalized muscle weakness are the most common presenting symptoms. Life-threatening renal failure and disseminated intravascular coagulation are dreaded complications that appear to be more common in adults.[6]

Rhabdomyolysis has many etiologies and is often multifactorial in adult patients. The physician must be alert to the diagnosis of rhabdomyolysis and to its subtle presentation to prevent acute renal failure. Sensitive laboratory markers of myocyte injury include elevated plasma creatine kinase (CK) levels. The management of rhabdomyolysis primarily consists of correction of fluid and electrolyte anomalies. With adequate supportive measures, the clinical outcome of rhabdomyolysis is often favorable in children.[2] Recurrent episodes of rhabdomyolysis may indicate underlying defects of muscle structure or metabolism.[7]

Next

Pathophysiology

Despite the multiple etiologies of rhabdomyolysis, the final common denominator appears to be disruption of the sarcolemma and release of intracellular myocyte components. Mechanisms of cell destruction in rhabdomyolysis include cellular membrane injury, muscle cell hypoxia, ATP depletion, and electrolyte disturbances that cause perturbation of sodium-potassium pumps.[2]

The sarcolemma, a thin membrane that encloses striated muscle fibers, contains numerous pumps that regulate cellular electrochemical gradients. The intercellular sodium concentration is normally maintained at 10 mEq/L by a sodium-potassium adenosine triphosphatase (Na/K-ATPase) pump located in the sarcolemma.[8]

The Na/K-ATPase pump actively transports sodium from the interior of the cell to the exterior. As a result, the interior of the cell is more negatively charged than the exterior because positive charges are transported across the membrane. The gradient pulls sodium to the interior of the cell in exchange for calcium through a protein carrier exchange mechanism. In addition, an active calcium exchanger promotes calcium entry into the sarcoplasmic reticulum and mitochondria.

The above processes depend on ATP as a source of energy. ATP depletion appears to be the end result of most causes of rhabdomyolysis. ATP depletion disrupts cellular transport mechanisms alters electrolyte composition.[9] An increase in intracellular calcium levels results in hyperactivity of proteases and proteolytic enzymes and generation of free oxygen radicals. These enzymes and substances increasingly degrade myofilaments and injure membrane phospholipid with leakage of intracellular contents into plasma. These contents include potassium, phosphate, CK, urate, and myoglobin. Excess fluid may also accumulate within affected muscle tissue. The action of phospholipases in insect and snake venom may cause hemolysis, muscle damage, endothelial necrosis, rhabdomyolysis, and acute renal injury.[10] Additionally, muscle damage is amplified by infiltration of activated neutrophils. An inflammatory cascade and reperfusion injury sustains muscle damage and degeneration.[11, 8]

Myoglobin is an important myocyte compound released into plasma (see image below). After muscle injury, massive plasma myoglobin levels exceed protein binding and can precipitate in glomerular filtrate. Excess myoglobin may thus cause renal tubular obstruction, direct nephrotoxicity (ischemia and tubular injury), intrarenal vasoconstriction, and acute renal failure.[6, 12, 7]

Model of helical domains in myoglobin, the proteinModel of helical domains in myoglobin, the protein linked to kidney damage in rhabdomyolysis.
Previous
Next

Epidemiology

Frequency

United States

Rhabdomyolysis is a common condition in adult populations and is understudied in pediatrics.[13, 2] The National Hospital Discharge Survey reports 26,000 cases annually.[13] Most adult cases of rhabdomyolysis are due to illicit drug abuse/alcohol abuse, muscular trauma and crush injuries, and myotoxic effects of prescribed drugs. Rhabdomyolysis is found in 24% of adult patients who present to emergency departments with cocaine-related conditions.

In a large adult cohort, 60% of cases had multiple factors.[13] Significant pediatric etiologies include infections, trauma, metabolic conditions, and muscle diseases. In a retrospective review at a tertiary care pediatric center review spanning 10 years viral myositis accounted for most cases in patients aged 0-9 years, whereas trauma was the leading diagnosis in patients aged 9-18 years.[2]

The incidence of myoglobin-induced acute renal failure in adult rhabdomyolysis ranges from 16-33%. This complication was found in 42% of pediatric patients in a small retrospective cohort study but in only 5% in the larger 10-year review mentioned above.[14, 2] Approximately 28-37% of adult patients require short-term hemodialysis. Rhabdomyolysis is believed to be responsible for 5-25% of all adult cases of acute renal failure. A comparable figure in children is unavailable.

International

Large numbers of patients may develop rhabdomyolysis and renal failure during disasters such as earthquakes. Severe crush injuries and delayed extrication of survivors characterize such events. Organizations such as the International Society of Nephrology have implemented measures to support local agencies in providing life-saving dialysis treatments for patients with rhabdomyolysis.[6]

Mortality/Morbidity

Electrolyte abnormalities are prominent features of rhabdomyolysis. Hyperphosphatemia, hyperkalemia, hypocalcemia, hyperuricemia, and hypoalbuminemia have been described.[1, 11]

Hyperkalemia may be a result of both muscle injury and renal insufficiency or failure. This abnormality may cause life-threatening arrhythmias and should be immediately addressed. Hypocalcemia is another common metabolic abnormality, resulting from deposition of calcium phosphate. It may also be due to a decreased level of 1,25-dihydroxycholecalciferol in patients with renal failure. Severe hypocalcemia may lead to cardiac arrhythmias, muscular contractions, and seizures. These events may further damage affected muscles. Hypoalbuminemia results from proteinuria and direct leakage of protein, whereas hyperuricemia is caused by direct damage to muscle and may contribute to renal tubular damage.

Compartment syndrome may be a complication of or an inciting cause of rhabdomyolysis. Muscle injury results from decreased tissue perfusion, which is caused by increased pressure within the affected space. High intracompartmental pressures mediate further ischemia, damage, and necrosis. Compartment pressures should be measured when significant muscle injury has occurred; a fasciotomy is advocated when the pressure is more than 30 mm Hg. Prolonged elevated intracompartmental pressure may lead to irreversible peripheral nerve injury.[6]

Acute renal failure is the most severe complication of rhabdomyolysis and may account for as many as 25% of adult cases of renal failure and 7-10% of acute kidney injuries in the United States.[13, 7]

Approximately one third of adult patients with rhabdomyolysis develop renal failure if not adequately treated. This figure may be as low as 5% in children.[13, 2] Mechanisms of renal failure are multifactorial and may include renal vasoconstriction, intraluminal myoglobin cast formation, and heme-protein cellular toxicity. Myoglobin and hemoglobin toxic effect on the glomerulus are enhanced by aciduria and hypovolemia.

Acute renal failure is believed to be due to decreased extracellular volume, which results in renal vasoconstriction. It is also believed to be due to ferrihemate, which is formed from myoglobin at a pH level of 5.6 or less. Ferrihemate produces free hydroxy radicals and causes direct nephrotoxicity, often through lipid peroxidation. These heme-proteins may enhance vasoconstriction through interactions with nitric oxide (NO) and endothelin receptors. The roles of cytokines in this process have also been discussed.[11]

Renal vasoconstriction and ischemia deplete tubular ATP formation and enhance tubular cell damage. Myoglobin precipitation in renal tubules causes formation of obstructive casts. Acute kidney injury rarely occurs in patients with chronic myopathies unless triggered by a second inciting event.[7] Risk of renal injury is low when initial CK levels are less than 15,000-20,000 U/L. Lower CK levels may lead to renal injury in patients with sepsis, dehydration, and/or acidosis.[7] GI ischemia is common in patients with fluid and electrolyte imbalances. This ischemia leads to endotoxin absorption, cytokine production, and perpetuation of the systemic inflammatory response.

Previous
 
 
Contributor Information and Disclosures
Author

Eyal Muscal, MD  Assistant Professor, Section of Pediatric Rheumatology, Department of Pediatrics, Baylor College of Medicine, Texas Children's Hospital

Eyal Muscal, MD is a member of the following medical societies: Alpha Omega Alpha, American College of Rheumatology, and Clinical Immunology Society

Disclosure: Nothing to disclose.

Coauthor(s)

Marietta Morales DeGuzman, MD  Assistant Professor, Department of Pediatrics, Baylor College of Medicine; Consulting Staff, Section of Pediatric Rheumatology, Department of Pediatrics, Texas Children's Hospital, Ben Taub General Hospital

Marietta Morales DeGuzman, MD is a member of the following medical societies: American Academy of Pediatrics, American College of Rheumatology, and Texas Pediatric Society

Disclosure: Nothing to disclose.

Specialty Editor Board

Barry L Myones, MD  Associate Professor, Departments of Pediatrics and Immunology, Pediatric Rheumatology Section, Baylor College of Medicine; Director of Research, Pediatric Rheumatology Center, Texas Children's Hospital

Barry L Myones, MD is a member of the following medical societies: American Academy of Pediatrics, American Association of Immunologists, American College of Rheumatology, American Heart Association, American Society for Microbiology, Clinical Immunology Society, and Texas Medical Association

Disclosure: Nothing to disclose.

Mary L Windle, PharmD  Adjunct Associate Professor, University of Nebraska Medical Center College of Pharmacy; Editor-in-Chief, Medscape Drug Reference

Disclosure: Nothing to disclose.

Herbert S Diamond, MD  Adjunct Professor of Medicine, Division of Rheumatology, University of Pittsburgh School of Medicine; Chairman Emeritus, Department of Internal Medicine, Western Pennsylvania Hospital

Herbert S Diamond, MD is a member of the following medical societies: Alpha Omega Alpha, American College of Physicians, American College of Rheumatology, American Medical Association, and Phi Beta Kappa

Disclosure: Merck Ownership interest Other; Smith Kline Ownership interest Other; Zimmer Ownership interest Other

Daniel Rauch, MD, FAAP  Director, Pediatric Hospitalist Program, Associate Professor, Department of Pediatrics, New York University School of Medicine

Daniel Rauch, MD, FAAP is a member of the following medical societies: Ambulatory Pediatric Association, American Academy of Pediatrics, and Society of Hospital Medicine

Disclosure: Baxter Honoraria Consulting

Chief Editor

Lawrence K Jung, MD  Chief, Division of Pediatric Rheumatology, Children's National Medical Center

Lawrence K Jung, MD is a member of the following medical societies: American Association for the Advancement of Science, American Association of Immunologists, American College of Rheumatology, Clinical Immunology Society, and New York Academy of Sciences

Disclosure: Nothing to disclose.

Additional Contributors

The authors and editors of eMedicine gratefully acknowledge the contributions of previous authors Renee Wilson, MD, and Binita R Shah, MD, FAAP, to the original writing and development of this article.

References
  1. Beetham R. Biochemical investigation of suspected rhabdomyolysis. Ann Clin Biochem. 2000;37:581-587. [Medline].

  2. Mannix R, Tan ML, Wright R, Baskin M. Acute pediatric rhabdomyolysis: causes and rates of renal failure. Pediatrics. Nov 2006;118(5):2119-25. [Medline].

  3. Cervellin G, Comelli I, Lippi G. Review: Rhabdomyolysis: historical background, clinical, diagnostic and therapeutic features. Clin Chem Lab Med. Mar 19 2010;[Medline].

  4. Gabow PA, Kaehny WD, Kelleher SP. The spectrum of rhabdomyolysis. Medicine (Baltimore). May 1982;61(3):141-52. [Medline].

  5. Watemberg N, Leshner RL, Armstrong BA, Lerman-Sagie T. Acute pediatric rhabdomyolysis. J Child Neurol. Apr 2000;15(4):222-7. [Medline].

  6. Vanholder R, Sever MS, Erek E, Lameire N. Rhabdomyolysis. J Am Soc Nephrol. Aug 2000;11(8):1553-61. [Medline]. [Full Text].

  7. Bosch X, Poch E, Grau JM. Rhabdomyolysis and acute kidney injury. N Engl J Med. Jul 2 2009;361(1):62-72. [Medline].

  8. Luck RP, Verbin S. Rhabdomyolysis review of clinical presentation, etiology, diagnosis and management. Pediatr Emerg Care. 2008;24:262-8. [Medline].

  9. Brumback RA, Feeback DL, Leech RW. Rhabdomyolysis in childhood. A primer on normal muscle function and selected metabolic myopathies characterized by disordered energy production. Pediatr Clin North Am. Aug 1992;39(4):821-58. [Medline].

  10. Sitprija V. Animal toxins and the kidney. Nat Clin Pract Nephrol. Nov 2008;4(11):616-27. [Medline].

  11. Huerta-Alardín AL, Varon J, Marik PE. Bench-to-bedside review: Rhabdomyolysis -- an overview for clinicians. Crit Care. Apr 2005;9(2):158-69. [Medline]. [Full Text].

  12. Paller MS. Hemoglobin- and myoglobin-induced acute renal failure in rats: role of iron in nephrotoxicity. Am J Physiol. Sep 1988;255(3 Pt 2):F539-44. [Medline].

  13. Melli G, Chaudhry V, Cornblath DR. Rhabdomyolysis: An Evaluation of 475 Hospitalized Patients. Medicine. 2005;84 (6):377-385. [Medline].

  14. Chamberlain MC. Rhabdomyolysis in children: a 3-year retrospective study. Pediatr Neurol. May-Jun 1991;7(3):226-8. [Medline].

  15. Bergeron MF, McKeag DB, Casa DJ, et al. Youth Football: Heat Stress and Injury Risk. Med Sci Sports Exerc. 2005;37 (8):1421-1430. [Medline].

  16. Hall AP, Henry JA. Acute toxic effects of 'Ecstasy' (MDMA) and related compounds: overview of pathophysiology and clinical management. Br J Anaesth. Jun 2006;96(6):678-85. [Medline].

  17. Coco TJ, Klasner AE. Drug-induced rhabdomyolysis. Curr Opin Pediatr. Apr 2004;16(2):206-10. [Medline].

  18. Singh U, Scheld WM. Infectious etiologies of rhabdomyolysis: three case reports and review. Clin Infect Dis. Apr 1996;22(4):642-9. [Medline].

  19. Lofberg M, Jankala H, Paetau A, et al. Metabolic causes of recurrent rhabdomyolysis. Acta Neurol Scand. Oct 1998;98(4):268-75. [Medline].

  20. Knochel JP. Hypophosphatemia and rhabdomyolysis. Am J Med. May 1992;92(5):455-7. [Medline].

  21. Pedrozzi NE, Ramelli GP, Tomasetti R, et al. Rhabdomyolysis and anesthesia: a report of two cases and review of the literature. Pediatr Neurol. Oct 1996;15(3):254-7. [Medline].

  22. Hollander AS, Olney RC, Blackett PR, Marshall BA. Fatal malignant hyperthermia-like syndrome with rhabdomyolysis complicating the presentation of diabetes mellitus in adolescent males. Pediatrics. 2003;111:1447-1452. [Medline]. [Full Text].

  23. Graham DJ, Staffa JA, Shatin D et al. Incidence of hospitalized rhabdomyolysis in patients treated with lipid lowering-drugs. JAMA. 2004;292:2585-2590. [Medline].

  24. Thompson PD, Clarkson P, Karas RH. Statin-associated myopathy. JAMA. Apr 2 2003;289(13):1681-90. [Medline].

  25. Urso ML, Clarkson PM, Hittel D, Hoffman EP, Thompson PD. Changes in ubiquitin proteasome pathway gene expression in skeletal muscle with exercise and statins. Arterioscler Thromb Vasc Biol. Dec 2005;25(12):2560-6. [Medline]. [Full Text].

  26. Joy TR, Hegele RA. Narrative review: statin-related myopathy. Ann Intern Med. Jun 16 2009;150(12):858-68. [Medline].

  27. Wiegman A, Hutten BA, de Groot E, et al. Efficacy and safety of statin therapy in children with familial hypercholesterolemia: a randomized controlled trial. JAMA. Jul 21 2004;292(3):331-7. [Medline].

  28. Hurley JK. Severe rhabdomyolysis in well conditioned athletes. Mil Med. May 1989;154(5):244-5. [Medline].

  29. Sinert R, Kohl L, Rainone T, Scalea T. Exercise-induced rhabdomyolysis. Ann Emerg Med. Jun 1994;23(6):1301-6. [Medline].

  30. Mehta R, Fisher LE Jr, Segeleon JE, Pearson-Shaver AL, and Wheeler DS. Acute rhabdomyolysis complicating status asthmaticus in children: case series and review. Pediatr Emerg Care. 2006;22:587-91. [Medline].

  31. Schwengel D, Ludwig S. Rhabdomyolysis and myoglobinuria as manifestations of child abuse. Pediatr Emerg Care. Dec 1985;1(4):194-7. [Medline].

  32. Peebles J, Losek JD. Child physical abuse and rhabdomyolysis: case report and literature review. Pediatr Emerg Care. Jul 2007;23(7):474-7. [Medline].

  33. Salluzzo R, Schwartz M, ed. Rhabdomyolysis. In: Emergency Clinical Practice. 4th ed. 1998:2478-86.

  34. [Guideline] Finnish Medical Society Duodecim. Rhabdomyolysis. In: EBM Guidelines. Evidence-Based Medicine [Internet]. Helsinki, Finland: Wiley Interscience. John Wiley & Sons; 2007 Apr 12. [Full Text].

  35. Better OS, Stein JH. Early management of shock and prophylaxis of acute renal failure in traumatic rhabdomyolysis. N Engl J Med. Mar 22 1990;322(12):825-9. [Medline].

  36. Gunn VL, Nechyba C, eds. The Harriet Lane Handbook. 16th ed. St Louis, MO: Mosby Elsevier, Inc.; 2002:45.

  37. Brown C, Rhee P, Chan L et al. Preventing renal failure in patients with rhabdomyolysis: do bicarbonate and mannitol make a difference?. J Trauma. 2004;56:1191-1196. [Medline].

  38. Sever MS, Vanholder R, Lameire N. Management of Crush-Related Injuries after Disasters. NEJM. 2006;Volume 354:1052-1063. [Medline].

  39. Thoenes M. Rhabdomyolysis: when exercising becomes a risk. J Pediatr Health Care. May-Jun 2010;24(3):189-93. [Medline].

Previous
Next
 
Model of helical domains in myoglobin, the protein linked to kidney damage in rhabdomyolysis.
 
 
 
All material on this website is protected by copyright, Copyright © 1994-2012 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.

DISCLAIMER: The content of this Website is not influenced by sponsors. The site is designed primarily for use by qualified physicians and other medical professionals. The information contained herein should NOT be used as a substitute for the advice of an appropriately qualified and licensed physician or other health care provider. The information provided here is for educational and informational purposes only. In no way should it be considered as offering medical advice. Please check with a physician if you suspect you are ill.